TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price traded down 5.6% during mid-day trading on Friday . The company traded as low as $4.34 and last traded at $4.36. 4,667,430 shares traded hands during trading, an increase of 84% from the average session volume of 2,540,797 shares. The stock had previously closed at $4.62.
A number of equities analysts have recently issued reports on the company. Oppenheimer Holdings, Inc. set a $10.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research report on Thursday, August 17th. Deutsche Bank AG initiated coverage on TherapeuticsMD in a report on Friday, July 21st. They issued a “buy” rating and a $10.00 target price for the company. Cowen and Company reiterated an “outperform” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Monday, July 17th. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Finally, Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a report on Friday, August 4th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $14.88.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative net margin of 485.71% and a negative return on equity of 74.25%. TherapeuticsMD’s quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.11) earnings per share. analysts forecast that TherapeuticsMD, Inc. will post -0.42 earnings per share for the current year.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were purchased at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the completion of the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at $21,294.45. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 23.92% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Candriam Luxembourg S.C.A. boosted its stake in TherapeuticsMD by 10.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after buying an additional 50,000 shares in the last quarter. Swiss National Bank boosted its stake in TherapeuticsMD by 12.3% during the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after buying an additional 31,800 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in TherapeuticsMD by 26.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after buying an additional 30,030 shares in the last quarter. Cetera Investment Advisers acquired a new stake in TherapeuticsMD during the second quarter worth $214,000. Finally, The Manufacturers Life Insurance Company boosted its stake in TherapeuticsMD by 3.4% during the second quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock worth $651,000 after buying an additional 4,058 shares in the last quarter. Hedge funds and other institutional investors own 71.54% of the company’s stock.
WARNING: “TherapeuticsMD, Inc. (TXMD) Shares Down 5.6%” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/11/04/therapeuticsmd-inc-txmd-shares-down-5-6.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
What are top analysts saying about TherapeuticsMD Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TherapeuticsMD Inc. and related companies.